The Medical Letter on Drugs and Therapeutics
Drugs for Helicobacter pylori Infection
The full article is available to subscribers Subscriber Login   
Revised 3/7/18: Information warning about an increased risk of cardiac events and death with clarithromycin has been added.

About 50% of the world’s population is infected with Helicobacter pylori. These gastric bacteria can cause chronic inflammation and have been associated with development of gastritis, peptic ulcer disease, gastric adenocarcinoma, and gastric mucosa-associated lymphoid tissue (MALT) lymphoma.1 Eradication of H. pylori can promote gastric healing, prevent recurrence of duodenal and gastric ulcers, and reduce the incidence of gastric cancer.2,3 Guidelines for treatment of H. pylori infection were updated recently.4-6

NONINVASIVE TESTING — Urea Breath Tests – A urea breath test (BreathTek; BreathID; PYtest) can be used for office-based diagnosis of H. pylori infection. The patient ingests a urea solution or urea-containing capsule labeled with a carbon ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Drugs for Helicobacter pylori Infection
Article code: 1525a
 Electronic, downloadable article - $25